Urinary Morbidity in Men Treated With Stereotactic Body Radiation Therapy (SBRT) for Localized Prostate Cancer Following Transurethral Resection of the Prostate (TURP)

Pepin, Abigail; Aghdam, Nima; Shah, Sarthak; Kataria, Shaan; Tsou, Harry; Datta, Subhradeep; Danner, Malika; Ayoob, Marilyn; Yung, Thomas M.; Lei, Siyuan; Gurka, Marie Kate; Collins, Brian T.; Krishnan, Pranay; Suy, Simeng; Hankins, Ryan; Lynch, John H.; Collins, Sean P.

doi:10.3389/fonc.2020.00555

Cited by 16 publications

(7 citation statements)

References 34 publications

(38 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this analysis, acute and late Radiation Therapy Oncology Group urinary toxicity were not significantly different between the TURP versus non-TURP cohorts. Finally, a cohort of 47 patients treated with SBRT (35e36.25 Gy in five fractions) with a history of prior TURP was retrospectively analysed in terms of physician-reported toxicities and patient-reported QoL [69]. With a mean follow-up of 4.7 years, late grade 2 and grade 3 genitourinary toxicity occurred in 48.9% and 6.4% men, respectively.…”

Section: Discussionmentioning

confidence: 99%

Ultrahypofractionated Radiotherapy for Localised Prostate Cancer: How Far Can We Go?

Corkum

Achard²,

Morton

et al. 2022

Clinical Oncology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Ultrahypofractionated Radiotherapy for Localised Prostate Cancer: How Far Can We Go?

Corkum

Achard²,

Morton

et al. 2022

Clinical Oncology

View full text Add to dashboard Cite

“…On the other hand, in another study matching 50 patients treated with prior TURP (patients with multiple TURP and/or previous adenomectomy were excluded) to a similar cohort of 50 consecutive patients who had no prior TURP before starting SBRT during the same period, this correlation was not observed [18]. Similarly, Pepin et al [19] in a retrospective analysis of 47 patients with a history of prior TURP (including multiple TURP) treated with prostate SBRT showed that genitourinary toxicity rates were overall comparable with patients treated with conventionally fractioned EBRT. Although direct comparisons between studies have many inherent limitations, toxicity results of our series suggest a possible increase in moderate and severe genitourinary toxicity following SBRT in patients with a previous history of TURP.…”

Section: Discussionmentioning

confidence: 93%

“…All patients were staged with multiparametric magnetic resonance imaging (mpMRI) of the prostate and bone scan in case of Gleason Score >7 and/or prostate-specific antigen >10 ng/ml. Eligible patients for SBRT presented a localised prostate cancer, with an International Prostate Symptom Score (IPSS) 19. Previous TURP or prostate adenomectomy procedures were allowed provided there was at least an 8-week interval with SBRT.…”

Section: Methodsmentioning

confidence: 99%

Surgical Treatments of Benign Prostatic Hyperplasia and Prostate Cancer Stereotactic Radiotherapy: Impact on Long-Term Genitourinary Toxicity

2022

View full text Add to dashboard Cite

“…Also, there is a concern that radical prostatectomy can be overtreatment as some patients will be reported as pT0. Radiotherapy is an effective treatment method with acceptable toxicity in patients who underwent TURP, incontinence rates are slightly higher compared to the patients without TURP (24,25). In this study, data on the continence status of patients who underwent radical prostatectomy and radiotherapy are lacking.…”

Section: Discussionmentioning

confidence: 96%

Incidental prostate cancer diagnosed after surgical treatment of benign prostatic hyperplasia

İlktaç¹,

Ersöz²,

Doğan³

et al. 2021

New J Urol.

View full text Add to dashboard Cite

Objective: Incidental prostate cancer (PCa) is defined as the clinically inapparent tumor detected after transurethral resection of prostate (TURP) or open prostatectomy with benign preoperative rectal examination, prostate specific antigen (PSA) and imaging. The aim of this study is to determine the incidence and clinical significance of incidental prostate cancer in our clinic. Material and Methods: A retrospective analysis was performed in patients who were treated with TURP or transvesical open prostatectomy (TVP) between January 2014 and December 2019. Age, prostate volume, preoperative PSA value, Gleason score, ISUP score, stage and presence of previous prostate biopsy were noted. Treatment performed for incidental PCA was determined. Results: A total of 1020 patients were surgically treated for benign prostate hyperplasia between January 2014 and December 2019. Incidental PCa was diagnosed in 57 (5.6%) patients. 51 (89%) of the patients had TURP and 6 (11%) had TVP. Mean age was 69.9±7.1 years and mean PSA value was 5.3±4.8 ng/ml. Majority of the patients (82.4%) had a Gleason score of 6 (3+3) and 37 (64.9%) patients were reported as stage 1a. Patients with preoperative prostate biopsy have significantly higher prostate volume and PSA values compared to the patients without biopsy (p<0.01). Active surveillance was performed in 42 patients, 2 patients underwent radical prostatectomy, 6 patients had radiotherapy and 7 patients had androgen blockade. Conclusion: We have an incidental PCa rate similar to the literature. Majority of the patients have stage 1a disease and a Gleason score of 6. Most of the patients were managed conservatively. Keywords: incidental prostate cancer, benign prostate hyperplasia, transurethral resection of prostate

show abstract

Urinary Morbidity in Men Treated With Stereotactic Body Radiation Therapy (SBRT) for Localized Prostate Cancer Following Transurethral Resection of the Prostate (TURP)

Cited by 16 publications

References 34 publications

Ultrahypofractionated Radiotherapy for Localised Prostate Cancer: How Far Can We Go?

Ultrahypofractionated Radiotherapy for Localised Prostate Cancer: How Far Can We Go?

Surgical Treatments of Benign Prostatic Hyperplasia and Prostate Cancer Stereotactic Radiotherapy: Impact on Long-Term Genitourinary Toxicity

Incidental prostate cancer diagnosed after surgical treatment of benign prostatic hyperplasia

Contact Info

Product

Resources

About